November 3, 2020 07:15 AM ESTUpdated November 4, 04:02 AM
Coronavirus

Covid-19 roundup: CEPI pours $328M in­to Clover's vac­cine; For­mer Shkre­li com­pa­ny li­cens­es po­ten­tial treat­ment for $20M

Nicole DeFeudis

Editor

Af­ter pour­ing $69.5 mil­lion in­to the de­vel­op­ment Clover Bio­phar­ma­ceu­ti­cals’ Covid-19 vac­cine, CEPI is back with an­oth­er $250 mil­lion-plus to fin­ish what it start­ed.

The lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

Iterum wins ap­proval for new oral an­tibi­ot­ic for UTIs. Now it wants a part­ner

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times